HER2 Mutations
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients (NCT05532696) | Anbogen Therapeutics, Inc. | 2022-09-27 |
Track HER2 Mutations automatically
Every clearance here is in the API, with alerts when new ones post.